Shamburg News · 8-K filed Nov 12, 2026, 4:05 PM EST

ADARx Pharmaceuticals Reports Third Quarter 2026 Results and Business Updates

ADRX · ADARx Pharmaceuticals, Inc.

  • Earnings
  • Financial statements
  • Other event
  • Reg FD disclosure
  • Materiality: high

ADARx Pharmaceuticals reported financial results for the third quarter ended September 30, 2026, with collaboration revenue of $2.2 million and a net loss of $28.1 million, compared with a net loss of $17.9 million a year earlier. The company said its IPO and concurrent private placement generated aggregate gross proceeds of approximately $602.5 million, and that cash is expected to fund operations into 2030. The release also reported that the FDA granted Fast Track designation to onvuzosiran for HAE in August 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, 9.01, accession 0001193125-26-458321.

Written from the filing by Shamburg Markets. Figures are as reported by the company.